Why can't I find REDEFINE 4 on ClinicalTrials.gov?

It has no registered acronym. Search the compound names instead — it is NCT06131437.

Why does fetching a ClinicalTrials.gov page return nothing?

It is a JavaScript application. The v2 API returns the same record as structured data.

Which fields matter most?

Status, enrolment, allocation and masking, and the primary outcome text — which states what the trial actually set out to show.

Research & Regulatory News

Searching a Trial Name Often Finds the Wrong Trial

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Trial names used in press coverage are frequently not registered acronyms. Searching ClinicalTrials.gov for REDEFINE 4 returns REDEFINE 1, 2 and 3 and never the trial itself, which is registered as NCT06131437 with no acronym at all.

Key facts

REDEFINE 4 registration: NCT06131437
Registered acronym: None
Searching 'REDEFINE 4' returns: REDEFINE 1, 2 and 3
Reliable search: Compound names, not trial names
Site is a JS app: Use the v2 API to read records
Wrong NCT IDs found here: Three, since corrected

Why trial names mislead

A programme name like REDEFINE or TRIUMPH is a sponsor's label for a family of studies, and individual members may or may not carry it as a registered acronym. REDEFINE 1, 2 and 3 do. The head-to-head against tirzepatide does not — its registry entry has no acronym field populated at all, so a name search cannot reach it.

What to search instead

Compound names and the comparison itself. Searching for the two drugs together returns the record immediately where the trial name fails. Then confirm identity from the official title, the enrolment number and the sponsor rather than from whichever entry appeared first.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Reading the record itself

ClinicalTrials.gov is a JavaScript application, so fetching the page often returns nothing useful. The v2 API returns structured data directly — an ordinary request for a study by its NCT number gives status, phase, enrolment, dates, allocation, masking, arms and primary outcome as plain fields.

The fields worth checking every time

Overall status, because trials change state. Enrolment, because reported figures drift. Allocation and masking, because open-label is a material limitation that press coverage omits. And the primary outcome text, which states what the trial actually set out to show — for NCT06131437 it reads as confirming non-inferiority, which is the whole context for what happened.

Why this site checks obsessively

Because three NCT identifiers published here were wrong, and one of them labelled TRIUMPH-1 pointed at an orforglipron trial — a different compound entirely. Every identifier now gets resolved against the registry before publication, and every trial referenced in this batch was pulled fresh from the API rather than recalled.

The check that takes ten seconds

Open the record. Read the official title. Confirm it names the compound you expect. A plausible-looking identifier from the right sponsor in the right format can still point at the wrong molecule, and reading the title is the step that catches it.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why can't I find REDEFINE 4 on ClinicalTrials.gov?: It has no registered acronym. Search the compound names instead — it is NCT06131437.
Why does fetching a ClinicalTrials.gov page return nothing?: It is a JavaScript application. The v2 API returns the same record as structured data.
Which fields matter most?: Status, enrolment, allocation and masking, and the primary outcome text — which states what the trial actually set out to show.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum